Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Xoma Royalty's Business Segments
Xoma Royalty's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
$ 12
Countrys Reported
2
Revenue Share by Reportable Segment - Q1 FY2026
- Single Reportable Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 12 | 100% |
Revenue Share by Country - Q1 FY2026
- CH54.4%
- US45.6%
Revenue by Geographic Country - Q1 FY2026
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| CH | $ 7 | 54.4% |
| US | $ 6 | 45.6% |
Description of Xoma Royalty
Xoma Corporation is a biotechnology company that specializes in the discovery, development, and commercialization of novel antibody-based therapeutics. Founded in 1981, the company is headquartered in Emeryville, California, and has a diversified portfolio of products targeting various diseases and indications.
The core focus of Xoma's research and development efforts lies in utilizing its proprietary antibody discovery and optimization platform, XomaGen, to identify and develop antibodies that target specific disease pathways. The company's approach involves harnessing the potential of monoclonal antibodies, which are laboratory-produced molecules designed to mimic the body's immune system responses.
Xoma has a strong track record of successful partnerships with industry-leading pharmaceutical and biotechnology companies, which has enabled the company to advance its pipeline of innovative therapeutics. These collaborations typically involve licensing and co-development agreements, where Xoma provides its expertise and capabilities in antibody discovery and development in exchange for upfront payments, milestone payments, and future royalties.
Currently, Xoma has a diverse portfolio of therapeutic candidates in various stages of development. One of its most notable products is gevokizumab, a potent monoclonal antibody that targets interleukin-1 beta, a pro-inflammatory protein implicated in several autoimmune and inflammatory diseases. Gevokizumab has demonstrated promising results in clinical trials for conditions such as pyoderma gangrenosum, Behcet's disease, and non-infectious uveitis.
Apart from gevokizumab, Xoma also has other product candidates in its pipeline, including XOMA 358 for the treatment of congenital hyperinsulinism, XOMA 213 for acute inflammatory demyelinating polyneuropathy, and XOMA 100 for the treatment of various tumors expressing the receptor tyrosine kinase MET.
In addition to its research and development activities, Xoma has a commercially-focused segment that licenses its technology and manufacturing capabilities to other companies. This segment allows Xoma to generate revenue through collaborations and partnerships beyond its internal product development efforts.
Overall, Xoma Corporation is a reputable biotechnology company that excels in the discovery, development, and commercialization of novel antibody-based therapeutics. With a strong portfolio of product candidates and strategic partnerships, the company is well-positioned to make significant contributions in the field of biotechnology and healthcare.
The core focus of Xoma's research and development efforts lies in utilizing its proprietary antibody discovery and optimization platform, XomaGen, to identify and develop antibodies that target specific disease pathways. The company's approach involves harnessing the potential of monoclonal antibodies, which are laboratory-produced molecules designed to mimic the body's immune system responses.
Xoma has a strong track record of successful partnerships with industry-leading pharmaceutical and biotechnology companies, which has enabled the company to advance its pipeline of innovative therapeutics. These collaborations typically involve licensing and co-development agreements, where Xoma provides its expertise and capabilities in antibody discovery and development in exchange for upfront payments, milestone payments, and future royalties.
Currently, Xoma has a diverse portfolio of therapeutic candidates in various stages of development. One of its most notable products is gevokizumab, a potent monoclonal antibody that targets interleukin-1 beta, a pro-inflammatory protein implicated in several autoimmune and inflammatory diseases. Gevokizumab has demonstrated promising results in clinical trials for conditions such as pyoderma gangrenosum, Behcet's disease, and non-infectious uveitis.
Apart from gevokizumab, Xoma also has other product candidates in its pipeline, including XOMA 358 for the treatment of congenital hyperinsulinism, XOMA 213 for acute inflammatory demyelinating polyneuropathy, and XOMA 100 for the treatment of various tumors expressing the receptor tyrosine kinase MET.
In addition to its research and development activities, Xoma has a commercially-focused segment that licenses its technology and manufacturing capabilities to other companies. This segment allows Xoma to generate revenue through collaborations and partnerships beyond its internal product development efforts.
Overall, Xoma Corporation is a reputable biotechnology company that excels in the discovery, development, and commercialization of novel antibody-based therapeutics. With a strong portfolio of product candidates and strategic partnerships, the company is well-positioned to make significant contributions in the field of biotechnology and healthcare.
Xoma Royalty Corporation is primarily engaged in the biopharmaceutical sector, focusing on the development and commercialization of innovative therapies for various diseases. The company operates through a unique business model that centers around royalties on the sale of proprietary products developed by other companies. Below are extensive descriptions of the segments, products, and services Xoma offers:
Segments
1. Royalty Interests:
- Xoma holds a diverse portfolio of royalty interests derived from agreements with various biopharmaceutical companies. These royalties stem from the sale of drugs developed using Xoma’s intellectual property.
- The portfolio includes royalties from compounds that have achieved regulatory approval and are in commercial distribution, thereby providing Xoma with a steady revenue stream without direct involvement in the manufacturing or marketing processes.
2. Collaborative Partnerships:
- The company engages in collaborative partnerships with biotechnology and pharmaceutical companies. These partnerships often involve shared research and development initiatives, wherein Xoma provides access to its proprietary technology in return for royalties or milestone payments.
- Collaborative efforts may also include co-development agreements where both parties contribute resources for the advancement of specific projects.
3. Therapeutic Areas:
- Xoma’s royalties span a range of therapeutic areas, including but not limited to, immunology, oncology, and infectious diseases. This therapeutic diversity is strategic in mitigating risk, as different segments may perform differently based on market demand, regulatory changes, and scientific advancements.
Products
1. Approved Products:
- Xoma benefits from royalties on a range of FDA-approved drugs, particularly focusing on products that utilize monoclonal antibody technologies. Some of these products target diseases that have significant unmet medical needs.
- Products that have gained acceptance for use in major treatment modalities represent a core element of Xomas royalty model, providing reliable income sources.
2. Pipeline Products:
- Xoma collaborates with companies engaged in clinical trials for promising therapeutic candidates. During this phase, Xoma’s involvement may involve initial funding or support in exchange for future royalties upon successful commercialization.
- This pipeline is continually evaluated for potential additions, targeting drugs that demonstrate strong clinical efficacy and safety profiles.
Services
1. Intellectual Property Management:
- Xoma offers services relating to the management and strategic licensing of its intellectual property portfolio. This includes assessing potential licensing opportunities and negotiating terms with biopharmaceutical companies interested in developing products based on Xoma’s patents.
2. Royalty Collection Services:
- Xoma has established systems for the efficient collection and management of royalties. This service includes tracking sales of licensed products and ensuring compliance with licensing agreements, which is essential for maintaining healthy revenue flows.
3. Business Development:
- The company engages in rigorous business development efforts to identify and pursue new royalty opportunities. This involves market analyses, assessments of competitive products, and outreach to potential partners who could benefit from Xoma’s intellectual property.
4. Regulatory Support:
- For the products in its royalty portfolio, Xoma often provides strategic insights that can help partners navigate the regulatory landscape. This may involve guidance based on its previous experiences and knowledge of the biopharmaceutical regulatory processes.
5. Market Access and Commercialization Support:
- Xoma assists partner companies in developing strategies for market access and commercialization. This can include advice on pricing strategies, reimbursement pathways, and creating value propositions that resonate with stakeholders and healthcare providers.
Conclusion
Xoma Royalty Corporation stands out in the biopharmaceutical field through its innovative royalty-based business model, extensive intellectual property portfolio, and strategic collaborations. By maintaining a focus on partnerships and diversifying its therapeutic segments, Xoma positions itself for sustainable growth while minimizing the risks typically associated with drug development and commercialization. Through its comprehensive services and proactive approach to market engagement, Xoma continues to be an influential player in the royalty landscape of the biopharmaceutical industry.
Segments
1. Royalty Interests:
- Xoma holds a diverse portfolio of royalty interests derived from agreements with various biopharmaceutical companies. These royalties stem from the sale of drugs developed using Xoma’s intellectual property.
- The portfolio includes royalties from compounds that have achieved regulatory approval and are in commercial distribution, thereby providing Xoma with a steady revenue stream without direct involvement in the manufacturing or marketing processes.
2. Collaborative Partnerships:
- The company engages in collaborative partnerships with biotechnology and pharmaceutical companies. These partnerships often involve shared research and development initiatives, wherein Xoma provides access to its proprietary technology in return for royalties or milestone payments.
- Collaborative efforts may also include co-development agreements where both parties contribute resources for the advancement of specific projects.
3. Therapeutic Areas:
- Xoma’s royalties span a range of therapeutic areas, including but not limited to, immunology, oncology, and infectious diseases. This therapeutic diversity is strategic in mitigating risk, as different segments may perform differently based on market demand, regulatory changes, and scientific advancements.
Products
1. Approved Products:
- Xoma benefits from royalties on a range of FDA-approved drugs, particularly focusing on products that utilize monoclonal antibody technologies. Some of these products target diseases that have significant unmet medical needs.
- Products that have gained acceptance for use in major treatment modalities represent a core element of Xomas royalty model, providing reliable income sources.
2. Pipeline Products:
- Xoma collaborates with companies engaged in clinical trials for promising therapeutic candidates. During this phase, Xoma’s involvement may involve initial funding or support in exchange for future royalties upon successful commercialization.
- This pipeline is continually evaluated for potential additions, targeting drugs that demonstrate strong clinical efficacy and safety profiles.
Services
1. Intellectual Property Management:
- Xoma offers services relating to the management and strategic licensing of its intellectual property portfolio. This includes assessing potential licensing opportunities and negotiating terms with biopharmaceutical companies interested in developing products based on Xoma’s patents.
2. Royalty Collection Services:
- Xoma has established systems for the efficient collection and management of royalties. This service includes tracking sales of licensed products and ensuring compliance with licensing agreements, which is essential for maintaining healthy revenue flows.
3. Business Development:
- The company engages in rigorous business development efforts to identify and pursue new royalty opportunities. This involves market analyses, assessments of competitive products, and outreach to potential partners who could benefit from Xoma’s intellectual property.
4. Regulatory Support:
- For the products in its royalty portfolio, Xoma often provides strategic insights that can help partners navigate the regulatory landscape. This may involve guidance based on its previous experiences and knowledge of the biopharmaceutical regulatory processes.
5. Market Access and Commercialization Support:
- Xoma assists partner companies in developing strategies for market access and commercialization. This can include advice on pricing strategies, reimbursement pathways, and creating value propositions that resonate with stakeholders and healthcare providers.
Conclusion
Xoma Royalty Corporation stands out in the biopharmaceutical field through its innovative royalty-based business model, extensive intellectual property portfolio, and strategic collaborations. By maintaining a focus on partnerships and diversifying its therapeutic segments, Xoma positions itself for sustainable growth while minimizing the risks typically associated with drug development and commercialization. Through its comprehensive services and proactive approach to market engagement, Xoma continues to be an influential player in the royalty landscape of the biopharmaceutical industry.